Mostrar el registro sencillo del documento

dc.creatorCitron, Francesca
dc.creatorPerelli, Luigi
dc.creatorDeem, Angela K.
dc.creatorGenovese, Giannicola
dc.creatorViale, Andrea
dc.date.accessioned2020-09-25T19:51:44Z
dc.date.available2020-09-25T19:51:44Z
dc.date.created2020
dc.identifier.issn0952-3278spa
dc.identifier.otherhttps://doi.org/10.1016/j.plefa.2020.102174spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/13822
dc.description.abstractRepositioning of clinically approved drugs that may reduce the severity, hospitalization events, and time of recovery from SARS-CoV2 infection is a global health priority. Clinical reports of drug effects and lung pathology are providing insight into the pathogenesis of Covid-19, and comparison of these findings with our knowledge of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) can be used to develop rational hypotheses to prioritize clinical studies of available therapeutics. Recently, Cao and colleagues [1] investigated the addition of a lopinavir-ritonavir regimen to standard of care, which previously showed promising activity in an open-label clinical study of patients affected by SARS [2]. However, lopinavir-ritonavir therapy did not confer any clinical benefit for patients with Covid-19, even when patients received glucocorticoids as a supportive drug [1]. Several agents, including remdesivir and chloroquine/hydroxychloroquine alone or in combination with azithromycin, were tested as potential treatment for Covid-19 patients, however available data are still not sufficient to delineate a definitive therapeutic approach [spa
dc.format.extent3 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherProstaglandins, Leukotrienes and Essential Fatty Acidsspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCovid-19spa
dc.subjectLeukotrienesspa
dc.titleLeukotrienes, a potential target for Covid-19spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1016/j.plefa.2020.102174spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Archivos en el documento

ArchivosTamañoFormatoVer

No hay archivos asociados a este documento.

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento